Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication

被引:490
作者
Benn, Marianne [1 ,2 ,5 ]
Watts, Gerald F. [3 ]
Tybjaerg-Hansen, Anne [2 ,4 ,5 ]
Nordestgaard, Borge G. [1 ,2 ,5 ]
机构
[1] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark
[2] Copenhagen Univ Hosp, Herlev Hosp, Copenhagen Gen Populat Study, DK-2730 Herlev, Denmark
[3] Univ Western Australia, Royal Perth Hosp, Lipid Disorders Clin, Sch Med & Pharmacol, Perth, WA 6000, Australia
[4] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth Sci, DK-1455 Copenhagen, Denmark
基金
英国医学研究理事会;
关键词
ASSOCIATION EXPERT PANEL; EUROPEAN COUNTRIES; HEART-DISEASE; PROSPECTIVE REGISTRY; GENETIC CAUSES; RISK-FACTORS; DIAGNOSIS; MANAGEMENT; RECOMMENDATIONS; DYSLIPIDAEMIAS;
D O I
10.1210/jc.2012-1563
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes. Objective: We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study. Setting: The study was of an unselected, community-based population comprising 69,016 participants. Main Outcome Measures: FH (definite/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris. Results: The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery or APOB mutation. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0-17.4) in definite/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8-13.8). Conclusion: The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol- lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care. (J Clin Endocrinol Metab 97: 3956-3964, 2012)
引用
收藏
页码:3956 / 3964
页数:9
相关论文
共 37 条
[1]   The paradox of public health genomics: Definition and diagnosis of familial hypercholesterolaemia in three European countries [J].
Aarden, Erik ;
Van Hoyweghen, Ine ;
Horstman, Klasien .
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2011, 39 (06) :634-639
[2]   2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension [J].
Afridi, I ;
Canny, J ;
Yao, CH ;
Christensen, B ;
Cooper, RS ;
Kadiri, S ;
Hill, S ;
Kaplan, N ;
Kuschnir, E ;
Lexchin, J ;
Mendis, S ;
Poulter, N ;
Psaty, BM ;
Rahn, KH ;
Sheps, SG ;
Whitworth, J ;
Yach, D ;
Bengoa, R ;
Ramsay, L ;
Kaplan, N ;
Mendis, S ;
Poulter, N ;
Whitworth, J .
JOURNAL OF HYPERTENSION, 2003, 21 (11) :1983-1992
[3]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[4]   Familial hypercholesterolemia and coronary heart disease: A HuGE association review [J].
Austin, MA ;
Hutter, CM ;
Zimmern, RL ;
Humphries, SE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (05) :421-429
[5]   Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review [J].
Austin, MA ;
Hutter, CM ;
Zimmern, RL ;
Humphries, SE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (05) :407-420
[6]   The new joint EAS/ESC guidelines for the management of dyslipidaemias [J].
Catapano, Alberico L. ;
Chapman, John ;
Wiklund, Olov ;
Taskinen, Marji-Riitta .
ATHEROSCLEROSIS, 2011, 217 (01) :1-1
[7]   The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population [J].
Damgaard, D ;
Larsen, ML ;
Nissen, PH ;
Jensen, JA ;
Jensen, HK ;
Soerensen, VR ;
Jensen, LG ;
Faergeman, O .
ATHEROSCLEROSIS, 2005, 180 (01) :155-160
[8]   Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia [J].
Daniels, Stephen R. ;
Gidding, Samuel. S. ;
de Ferranti, Sarah D. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (03) :S30-S37
[9]   Silent ischaemia in familial hypercholesterolemia [J].
Descamps, OS ;
de Meester, A ;
Cheron, P ;
Kastelein, JJ ;
Heller, FR .
ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (03) :7-8
[10]   Implementation of cascade testing for the detection of familial hypercholesterolaemia [J].
Hadfield, SG ;
Humphries, SE .
CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (04) :428-433